UBI Pharma
One-Stop Shop for Ideation to Commercialization

Pharmaceutical contract development and manufacturing organizations (CDMO) stood the test of time during the initial COVID-19 breakout, juggling restrictions and worker safety to produce essential medication. One organization, however, faced the challenge head-on, maintaining a steady production line without disrupting its supply capabilities. Combined with its strict supplier management, stable supplier relationship, and extensive distribution network, it propelled the market share of one of its client’s drugs by four times over the last three years amid the chaos caused by COVID-19.

This success is attributed to UBI Pharma, a game-changing CDMO that serves many of the top multinational pharmaceuticals to produce drugs of various dosage types while mainly focusing on sterile injections. “Our production lines manufacture products compliant with international pharma standards and currently sold in Taiwan, Hong Kong, Japan, ASEAN countries, and the U.S.,” says Dr. Roger Kuo, COO of UBI Pharma.

UBI Pharma’s consistent manufacturing and delivery abilities result from its proactive management style that nips issues in the bud. Upon receiving information that one of its main materials required for production would be discontinued or the lead time is unpredictable, the UBI Pharma team immediately sources and uses an alternative material, minimizing any negative impact on the client without disturbing production flow or product quality.

UBI Pharma provides a comprehensive service to clients, from developing early lab batches to the product’s commercialization, including material sourcing, developing custom assays, and packaging design. Every product goes through various stages of development, testing, and inspection. They’re marked using a proven serialization system that matches current legislation and can be updated for future regulatory changes. Its in-house project management team ensures the entire operation is sustainable and matches client requirements, while a regulatory affairs team assists them in preparing common technical documents for drug registrations.

Its workflow allows for swift commercialization, made possible due to its arsenal of experienced personnel.

UBI Pharma also has a hand in the R&D side of biopharmaceuticals, its star of the show is a self-developed long-acting protein drug development technology and a unique fusion protein technology platform with the potential to surpass many patented technologies in the market. UBI Pharma has also developed a technology platform specifically for polysaccharide-protein fusion. It houses multiple glycosylation sites that can connect to 50 sialic acid residues at a time, delaying the sialidase’s action while reducing the protein breakdown rate in the body and extending the protein’s half-life.

UBI Pharma’s manufacturing base is an internationally qualified facility where it manufactures for many top pharmaceutical companies. The building spans over 240,000 square feet and houses 260 professional production experts and researchers. It produces 11,200,000 vial injections annually and is creating a new production line that will quadruple the annual capacity with maximum batch sizes of 500 liters to meet the growing global demand for injectables. Scaling its injectable line helps UBI Pharma combat the rising cost of raw materials by reducing manufacturing costs.

Numerous reputed institutions can attest to the quality of UBI Pharma’s products. Its sterile injectable line was one of the first in Taiwan to be inspected by the U.S. FDA, and it regularly tenders controlled drugs to the local government. UBI Pharma manufactures liquid injectables, ampoules, and lyophilized products and is working with ASEAN and U.S. partners to expand distribution. It is also looking to add pre-filled syringes, painless pens, and cartridges to its product line.

Delivering high-quality and cost-effective products while driving innovation in the pharma tech sector, UBI Pharma is a leading vendor that clients turn to for reliable, efficient, and all-in-one pharma CDMO services.